Do Transparent Capsule Inhalers Improve Medication Delivery?
Researchers investigated whether transparent capsules in dry powder inhalers improved medication delivery by providing visual feedback to patients.
Researchers investigated whether transparent capsules in dry powder inhalers improved medication delivery by providing visual feedback to patients.
Researchers investigated whether transparent capsules in dry powder inhalers improved medication delivery by providing visual feedback to patients.
Read MoreStarting June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers, the company says.
Read MoreAAFA says the investigation opens an opportunity to address what patients report as the primary reason why people don’t adhere to their asthma treatment: the cost of prescribed asthma medication.
Read MoreTheravance Biopharma’s COPD treatment Yupelri was not superior to Boehringer Ingelheim’s Spiriva Handihaler, according to results from a phase 4 study reported by Theravance.
Read MoreThe US Food and Drug Administration accepted a supplemental New Drug Application for an expanded indication of ofev (nintedanib) to treat children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease.
Read MoreBoehringer Ingelheim’s BI 1015550 is a PDE4B inhibitor with the potential to address both pulmonary fibrosis and inflammation associated with progressive fibrosing interstitial lung diseases.Â
Read MoreThe FDA approved Pradaxa oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days.
Read MoreThe US FDA has approved Boehringer Ingelheim’s Ofev (nintedanib) to treat chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.
Read MoreThe FDA has granted Ofev (nintedanib) a breakthrough therapy designation for chronic fibrosing interstitial lung disease, according to Boehringer Ingelheim.
Read MoreThe Arthritis Foundation recognized Respimat with its Ease of Use Commendation for products proven to make life easier for people with arthritis and other physical limitations.
Read MoreSeveral new pharmacological treatments for COPD and asthma have appeared on the respiratory market in the past year but what are the advantages these new generation pharmaceuticals?
Read MoreNew analyses presented at ATS 2016 further add to the efficacy and safety profile of Ofev (nintedanib) in idiopathic pulmonary fibrosis (IPF).
Read MorePropeller Health and Boehringer Ingelheim are launching a first-of-its-kind commercial partnership to help people living with COPD and asthma better manage their disease.
Read MoreStudies showed consistent improvement in lung function across a range of ages using Stiolto compared to tiotropium, olodaterol or placebo.
Read MoreStiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States, according to manufacturer Boehringer Ingelheim Pharmaceuticals.
Read MoreAccording to five Phase III trials, lung function significantly improved with the addition of tiotropium delivered via the Respimat inhaler compared to placebo, irrespective of underlying allergic status.
Read MoreBoehringer Ingelheim Pharmaceuticals Inc’s New Drug Application (NDA) for its investigational compound nintedanib has been accepted for filing by the FDA and granted Priority Review designation.
Read MoreThe FDA has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in certain patients, according to Boehringer Ingelheim Pharmaceuticals.
Read MoreFor asthma patients who remain symptomatic despite current treatment options, clinical trials looking at the effectiveness of an add-on aerosol therapy using tiotropium could provide potential relief.
Read MoreThe company has completed enrollment for two phase III studies evaluating the safety and efficacy of nintedanib, an investigation compound, in patients with indiopathic pulmonary fibrosis.
Read MoreThis is the second FDA-approved indication for Spiriva Handihaler, which was already approved as a once-daily treatment for breathing problems associated with COPD.
Read MoreA new educational and interactive campaign called The Breathing Room was launched today to help educate people about COPD and encourage those experiencing its symptoms to talk to their physicians about getting screened.
Read More